- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03920293
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Wien, Austria, 1090
- Clinical Trial Site
-
-
-
-
-
Montreal, Canada, H3A2B4
- Clinical Trial Site
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4Z6
- Clinical Trial Site
-
Edmonton, Alberta, Canada, T6G 2B7
- Clinical Trial Site
-
-
Ontario
-
London, Ontario, Canada, N6A 5A5
- Clinical Trial Site
-
Toronto, Ontario, Canada, M5G 2C4
- Clinical Trial Site
-
-
-
-
-
Brno, Czechia, 62500
- Clinical Trial Site
-
Prague, Czechia, 140 59
- Clinical Trial Site
-
-
Czech Republic
-
Prague, Czech Republic, Czechia, 128 01
- Clinical Trial Site
-
-
Moravian-Silesian
-
Ostrava, Moravian-Silesian, Czechia, 708 52
- Clinical Trial Site
-
-
-
-
Hovedstaden
-
Copenhagen, Hovedstaden, Denmark, 2100
- Clinical Trial Site
-
-
Jutland
-
Aarhus N, Jutland, Denmark, 8200
- Clinical Trial Site
-
-
North Jutland Region
-
Aalborg, North Jutland Region, Denmark, 9000
- Clinical Trial Site
-
-
-
-
-
Garches, France, 92380
- Clinical Trial Site
-
-
Cedex
-
Lille, Cedex, France, 59037
- Clinical Trial Site
-
-
Provence-Alpes-Cote d'Azur
-
Marseille, Provence-Alpes-Cote d'Azur, France, 13385
- Clinical Trial Site
-
Nice, Provence-Alpes-Cote d'Azur, France, 6000
- Clinical Trial Site
-
-
-
-
-
Berlin, Germany, D-10117
- Clinical Trial Site
-
Hamburg, Germany, 20246
- Clinical Trial Site
-
Hannover, Germany, 30625
- Clinical Trial Site
-
-
Bavaria
-
Würzburg, Bavaria, Germany, 97070
- Clinical Trial Site
-
-
Nordrhein-Westfalen
-
Essen, Nordrhein-Westfalen, Germany, 45147
- Clinical Trial Site
-
Münster, Nordrhein-Westfalen, Germany, 48149
- Clinical Trial Site
-
-
Sachsen-Anhalt
-
Halle, Sachsen-Anhalt, Germany, 6120
- Clinical Trial Site
-
-
Saxony
-
Leipzig, Saxony, Germany, 04103
- Clinical Trial Site
-
-
-
-
Hefa
-
Haifa, Hefa, Israel, 3109601
- Clinical Trial Site
-
-
Tel-Aviv
-
Tel Aviv-Yafo, Tel-Aviv, Israel, 64239
- Clinical Trial Site
-
-
-
-
Emilia-Romagna
-
Bologna, Emilia-Romagna, Italy, 40139
- Clinical Trial Site
-
-
Genoa
-
Genova, Genoa, Italy, 16132
- Clinical Trial Site
-
-
Lombardia
-
Milan, Lombardia, Italy, 20133
- Clinical Trial Site
-
-
Roma
-
Bergamo, Roma, Italy, 24127
- Clinical Trial Site
-
Rome, Roma, Italy, 00168
- Clinical Trial Site
-
Rome, Roma, Italy, 00189
- Clinical Trial Site
-
-
Sicilia
-
Messina, Sicilia, Italy, 98124
- Clinical Trial Site
-
-
-
-
-
Hanamaki-shi, Japan, 025-0075
- Clinical Trial Site
-
Tokyo, Japan, 100-0001
- Clinical Trial Site
-
-
Aichi
-
Nagoya-shi, Aichi, Japan, 466-8560
- Clinical Trial Site
-
-
Chiba
-
Chuo Ku, Chiba, Japan, 260-8677
- Clinical Trial Site
-
-
Fukuoka
-
Fukuoka-shi, Fukuoka, Japan, 812-8582
- Clinical Trial Site
-
-
Hokkaido
-
Sapporo-shi, Hokkaido, Japan, 060-8543
- Clinical Trial Site
-
-
Ishikawa
-
Kanazawa-shi, Ishikawa, Japan, 920-8641
- Clinical Trial Site
-
-
Miyagi
-
Sendai-shi, Miyagi, Japan, 120-0047
- Clinical Trial Site
-
-
Nagasaki
-
Nagasaki-shi, Nagasaki, Japan, 852-8501
- Clinical Trial Site
-
-
Niigata
-
Niigata-shi, Niigata, Japan, 951-8520
- Clinical Trial Site
-
-
Osaka
-
Izumi-Shi, Osaka, Japan, 594-0073
- Clinical Trial Site
-
Moriguchi-shi, Osaka, Japan, 570-8507
- Clinical Trial Site
-
Osaka Sayama-shi, Osaka, Japan, 5898511
- Clinical Trial Site
-
Suita-shi, Osaka, Japan, 565-0871
- Clinical Trial Site
-
Toyonaka-shi, Osaka, Japan, 560-8552
- Clinical Trial Site
-
-
Saitama
-
Kawagoe-shi, Saitama, Japan, 350-8550
- Clinical Trial Site
-
-
Sapporo
-
Sapporo-shi, Sapporo, Japan, 0630005
- Clinical Trial Site
-
-
Tokyo
-
Bunkyō-Ku, Tokyo, Japan, 113-8431
- Clinical Trial Site
-
Bunkyō-Ku, Tokyo, Japan, 113-8655
- Clinical Trial Site
-
Shinjuku-Ku, Tokyo, Japan, 160-8582
- Clinical Trial Site
-
-
Yamaguchi
-
Ube-shi, Yamaguchi, Japan, 755-8505
- Clinical Trial Site
-
-
-
-
-
Daegu, Korea, Republic of, 41404
- Clinical Trial Site
-
Seoul, Korea, Republic of, 02841
- Clinical Trial Site
-
Seoul, Korea, Republic of, 03722
- Clinical Trial Site
-
Seoul, Korea, Republic of, 05505
- Clinical Trial Site
-
Seoul, Korea, Republic of, 06351
- Clinical Trial Site
-
Seoul, Korea, Republic of, 05030
- Clinical Trial Site
-
Seoul, Korea, Republic of, 3080
- Clinical Trial Site
-
-
Gyeongsangnam-do
-
Yangsan, Gyeongsangnam-do, Korea, Republic of, 50612
- Clinical Trial Site
-
-
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Netherlands, 1105 AZ
- Clinical Trial Site
-
Leiden, Noord-Holland, Netherlands, 2333 ZA
- Clinical Trial Site
-
-
-
-
-
Porto, Portugal, 4099-001
- Clinical Trial Site
-
-
-
-
-
Barcelona, Spain, 08035
- Clinical Trial Site
-
Barcelona, Spain, 08907
- Clinical Trial Site
-
Barcelona, Spain, 8025
- Clinical Trial Site
-
Barcelona, Spain, 8036
- Clinical Trial Site
-
Madrid, Spain, 28040
- Clinical Trial Site
-
Madrid, Spain, 28034
- Clinical Trial Site
-
Madrid, Spain, 28046
- Clinical Trial Site
-
Murcia, Spain, 30120
- Clinical Trial Site
-
Valencia, Spain, 46026
- Clinical Trial Site
-
-
Bizkaia
-
Barakaldo, Bizkaia, Spain, 48903
- Clinical Trial Site
-
-
-
-
-
Zürich, Switzerland, 8091
- Clinical Trial Site
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85013-4409
- Clinical Trial Site
-
Phoenix, Arizona, United States, 85018
- Clinical Trial Site
-
Phoenix, Arizona, United States, 85082
- Clinical Trial Site
-
-
California
-
Loma Linda, California, United States, 92354
- Clinical Trial Site
-
Los Angeles, California, United States, 90048
- Clinical Trial Site
-
Orange, California, United States, 92868
- Clinical Trial Site
-
Palo Alto, California, United States, 94304
- Clinical Trial Site
-
San Francisco, California, United States, 94109
- Clinical Trial Site
-
Sylmar, California, United States, 91342
- Clinical Trial Site
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Clinical Trial Site
-
Colorado Springs, Colorado, United States, 80907
- Clinical Trial Site
-
Fort Collins, Colorado, United States, 80528
- Clinical Trial Site
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Clinical Trial Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Clinical Trial Site
-
-
Florida
-
Clearwater, Florida, United States, 33761
- Clinical Trial Site
-
Jacksonville, Florida, United States, 32209
- Clinical Trial Site
-
Tampa, Florida, United States, 33612
- Clinical Trial Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Clinical Trial Site
-
Augusta, Georgia, United States, 30912
- Clinical Trial Site
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Clinical Trial Site
-
Chicago, Illinois, United States, 60637
- Clinical Trial Site
-
Rolling Meadows, Illinois, United States, 60008
- Clinical Trial Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Clinical Trial Site
-
-
Kansas
-
Fairway, Kansas, United States, 66205
- Clinical Trial Site
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- Clinical Trial Site
-
Lexington, Kentucky, United States, 40503
- Clinical Trial Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Clinical Trial Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Clinical Trial Site
-
Burlington, Massachusetts, United States, 08013
- Clinical Trial Site
-
-
Michigan
-
East Lansing, Michigan, United States, 48824
- Clinical Trial Site
-
Grand Rapids, Michigan, United States, 49503
- Clinical Trial Site
-
-
Minnesota
-
Detroit Lakes, Minnesota, United States, 48201
- Clinical Trial Site
-
-
Missouri
-
Columbia, Missouri, United States, 65212
- Clinical Trial Site
-
Saint Louis, Missouri, United States, 63110
- Clinical Trial Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89106
- Clinical Trial Site
-
Las Vegas, Nevada, United States, 89145
- Clinical Trial Site
-
-
New York
-
East Setauket, New York, United States, 11733
- Clinical Trial Site
-
Great Neck, New York, United States, 11021
- Clinical Trial Site
-
New York, New York, United States, 10021
- Clinical Trial Site
-
New York, New York, United States, 10075
- Clinical Trial Site
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Clinical Trial Site
-
Charlotte, North Carolina, United States, 28207
- Clinical Trial Site
-
Durham, North Carolina, United States, 27710
- Clinical Trial Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Clinical Trial Site
-
Cleveland, Ohio, United States, 44195
- Clinical Trial Site
-
Cleveland, Ohio, United States, 44106
- Clinical Trial Site
-
Columbus, Ohio, United States, 43210
- Clinical Trial Site
-
Columbus, Ohio, United States, 43214
- Clinical Trial Site
-
-
Oregon
-
Springfield, Oregon, United States, 97499
- Clinical Trial Site
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Clinical Trial Site
-
Philadelphia, Pennsylvania, United States, 19104
- Clinical Trial Site
-
Philadelphia, Pennsylvania, United States, 19104-4206
- Clinical Trial Site
-
-
South Carolina
-
Charleston, South Carolina, United States, 29406
- Clinical Trial Site
-
Charleston, South Carolina, United States, 29459
- Clinical Trial Site
-
-
Tennessee
-
Cordova, Tennessee, United States, 38018
- Clinical Trial Site
-
Nashville, Tennessee, United States, 37232
- Clinical Trial Site
-
-
Texas
-
Austin, Texas, United States, 78753
- Clinical Trial Site
-
Dallas, Texas, United States, 75214
- Clinical Trial Site
-
Houston, Texas, United States, 77030
- Clinical Trial Site
-
Round Rock, Texas, United States, 78681
- Clinical Trial Site
-
San Antonio, Texas, United States, 78229
- Clinical Trial Site
-
-
Vermont
-
Burlington, Vermont, United States, 05405
- Clinical Trial Site
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Clinical Trial Site
-
-
Washington
-
Seattle, Washington, United States, 98122
- Clinical Trial Site
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- Clinical Trial Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53215
- Clinical Trial Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosed with Myasthenia Gravis at least 6 months (180 days) prior to the date of the Screening Visit as confirmed by specific criteria.
- Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at screening.
- MG-ADL profile must be ≥ 6 at screening and randomization (Day 1).
- Vaccinated against meningococcal infections within 3 years prior to, or at the time of, initiating study drug to reduce the risk of meningococcal infection (N meningitidis).
Exclusion Criteria:
Medical Conditions
- Any active or untreated thymoma. History of thymic carcinoma or thymic malignancy unless deemed cured by adequate treatment with no evidence of recurrence for ≥ 5 years before screening.
- History of thymectomy within the 12 months prior to screening.
- History of N meningitidis infection.
Use of the following within the time period specified below:
- IV immunoglobulin within 4 weeks of randomization
- Use of plasma exchange within 4 weeks of randomization
- Use of rituximab within 6 months of screening
- Participants who have received previous treatment with complement inhibitors (for example, eculizumab).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ravulizumab
Participants will receive ravulizumab for the duration of the study.
|
Concentrated sterile, preservative-free aqueous solution (10 milligrams [mg]/milliliter [mL]) in single-use, 30-mL vial for intravenous (IV) infusion.
Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
Other Names:
|
Placebo Comparator: Placebo
Participants will receive placebo during the 26-week randomized-controlled period of the study, after which they will enter the open-label extension period of the study and receive ravulizumab.
|
Matching, sterile, preservative-free aqueous solution in single-use, 30-mL vial for IV infusion.
Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline In Myasthenia Gravis-Activities Of Daily Living (MG-ADL) Total Score At Week 26
Time Frame: Baseline, Week 26
|
The MG-ADL is an 8-point questionnaire that focused on relevant symptoms and functional performance of activities of daily living in participants with MG.
The 8 items of the MGADL questionnaire were derived from symptom-based components of the original 13-item QMG scale to assess disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG.
In this functional status instrument, each response was graded 0 (normal) to 3 (most severe).
The range of total MG-ADL score was 0 to 24.
A decrease in score indicated improvement.
Estimates were based on Mixed Effect Repeated Measures (MMRM) that included treatment group, stratification factor region, and MG-ADL total score at baseline, study visit, and study visit by treatment group interaction.
|
Baseline, Week 26
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline In The Quantitative Myasthenia Gravis (QMG) Total Score At Week 26
Time Frame: Baseline, Week 26
|
The QMG scoring system consisted of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item); each graded 0 to 3, with 3 being the most severe.
The range of total QMG score is 0 to 39.
The QMG scoring system was considered to be an objective evaluation of therapy for MG and was based on quantitative testing of sentinel muscle groups.
A decrease in score indicated improvement.
Estimates were based on MMRM that included treatment group, stratification factor region, and QMG total score at baseline, study visit, and study visit by treatment group interaction.
|
Baseline, Week 26
|
Percentage of Participants With a Quantitative Myasthenia Gravis (QMG) Total Score Reduction of at Least 5 Points At Week 26
Time Frame: Week 26
|
The QMG scoring system consisted of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item); each graded 0 to 3, with 3 being the most severe.
The range of total QMG score is 0 to 39.
A decrease in score indicated improvement.
Percentage of participants with a ≥5-point reduction in the QMG total score are reported.
Estimates were based on a generalized linear mixed model (GLMM) that included treatment group, stratification factor region and QMG total score at baseline, study visit and study visit by treatment group interaction.
|
Week 26
|
Change From Baseline In the Revised 15 Component Myasthenia Gravis Quality of Life (MG-QOL15r) At Week 26
Time Frame: Baseline, Week 26
|
The revised Myasthenia Gravis Qualify of Life 15-item scale (MG-QOL15r) is a health-related QoL evaluative instrument specific to participants with MG. The MG-QOL15r was designed to provide information about participants' perception of impairment and disability, determine the degree to which disease manifestations are tolerated, and to be administered and interpreted easily. Each item was graded on a scale of 0 to 2, with 2 being the most severe. The range of MG-QOL15r score is 0 to 30. Higher scores indicated greater extent of and dissatisfaction with MG-related dysfunction. Estimates are based on MMRM that included treatment group, stratification factor region and MG-QOL15r score at baseline, study visit and study visit by treatment group interaction. |
Baseline, Week 26
|
Change From Baseline in Neurological Quality of Life (Neuro-QoL) Fatigue Score at Week 26
Time Frame: Baseline, Week 26
|
The Neuro-QOL Fatigue is a reliable and validated brief 19-item survey of fatigue, completed by the participant.
Each items was rated on a scale of 1 to 5, with 5 being the most severe.
The range of total score is 19 to 95.
Higher scores indicated greater fatigue and greater impact of MG on activities.
Estimates were based on MMRM that included treatment group, stratification factor region and Neuro-QoL Fatigue score at baseline, study visit, and study visit by treatment group interaction.
|
Baseline, Week 26
|
Percentage of Participants With a Myasthenia Gravis Activities of Daily Living (MG-ADL) Total Score Reduction of at Least 3 Points At Week 26
Time Frame: Week 26
|
The MG-ADL is an 8-point questionnaire that focused on relevant symptoms and functional performance of activities of daily living in participants with MG.
The 8 items of the MGADL questionnaire were derived from symptom-based components of the original 13-item QMG scale to assess disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG.
In this functional status instrument, each response was graded 0 (normal) to 3 (most severe).
The range of total MG-ADL score was 0 to 24.
A decrease in score indicated improvement.
Percentage of participants with a ≥3-point reduction in the MG-ADL total score are reported.
Estimates were based on a GLMM that included treatment group, stratification factor region and MG-ADL total score at baseline, study visit and study visit by treatment group interaction.
|
Week 26
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Neoplasms
- Autoimmune Diseases of the Nervous System
- Autoimmune Diseases
- Neoplasms by Site
- Neurologic Manifestations
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Neuromuscular Manifestations
- Nervous System Neoplasms
- Paraneoplastic Syndromes, Nervous System
- Paraneoplastic Syndromes
- Neuromuscular Junction Diseases
- Muscle Weakness
- Myasthenia Gravis
- Physiological Effects of Drugs
- Immunosuppressive Agents
- Immunologic Factors
- Complement Inactivating Agents
- Ravulizumab
Other Study ID Numbers
- ALXN1210-MG-306
- 2018-003243-39 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Generalized Myasthenia Gravis
-
Assiut UniversityRecruitingNervous System Diseases | Autoimmune Diseases of the Nervous System | Thymoma | Myasthenia Gravis | Neuromuscular Junction Diseases | Myasthenia Gravis, Generalized | Myasthenia Gravis Crisis | Myasthenia Gravis, Ocular | Myasthenia Gravis, Juvenile Form | Thymus Hyperplasia | Myasthenia Gravis With Exacerbation... and other conditionsEgypt
-
Alexion Pharmaceuticals, Inc.CompletedMyasthenia Gravis | Myasthenia Gravis, Generalized | Myasthenia Gravis, Juvenile FormUnited States, Japan, Netherlands
-
Catalyst Pharmaceuticals, Inc.CompletedMyasthenia Gravis, GeneralizedUnited States
-
COUR Pharmaceutical Development Company, Inc.Not yet recruitingMyasthenia Gravis | Generalized Myasthenia | AChR Myasthenia Gravis | MuSK MGUnited States
-
University of Missouri-ColumbiaUniversity of Kansas Medical CenterRecruitingGeneralized Myasthenia GravisUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
Alexion Pharmaceuticals, Inc.RecruitingGeneralized Myasthenia GravisChina, United States, Spain, United Kingdom, Korea, Republic of, Italy, Germany, Japan, Brazil, France, Netherlands, Taiwan, Turkey, Israel, Poland, Austria, Denmark, Portugal, Canada, Serbia, Argentina, Switzerland
-
Immunovant Sciences GmbHRecruitingGeneralized Myasthenia GravisUnited States, Poland, Romania, Italy, Georgia, Korea, Republic of, Canada, Japan, Hungary, Spain, Serbia, Germany
-
argenxActive, not recruitingGeneralized Myasthenia GravisUnited States, Belgium, Czechia, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain
-
Alexion Pharmaceuticals, Inc.Active, not recruitingGeneralized Myasthenia Gravis | Myasthenia GravisUnited States, Spain, Korea, Republic of, Canada, Germany, Italy, Serbia, Taiwan
Clinical Trials on Ravulizumab
-
AlexionCompletedParoxysmal Nocturnal HemoglobinuriaBelgium, Brazil, France, Italy, Spain, Australia, Canada, Sweden, Russian Federation, Austria, United States, Netherlands, Turkey, Finland
-
BioCryst PharmaceuticalsTerminatedBCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy (REDEEM-1)Paroxysmal Nocturnal Hemoglobinuria (PNH)United Kingdom, Hungary, France, Italy, Spain
-
Brigham and Women's HospitalActive, not recruiting
-
Alexion Pharmaceuticals, Inc.CompletedAtypical Hemolytic Uremic Syndrome (aHUS)United States, France, Spain, Taiwan, United Kingdom, Australia, Belgium, Germany, Italy, Japan, Korea, Republic of, Russian Federation, Austria, Canada
-
Alexion Pharmaceuticals, Inc.CompletedHealthyUnited Kingdom
-
Alexion PharmaceuticalsCompletedParoxysmal Nocturnal Hemoglobinuria | PNHKorea, Republic of, Canada, France, Germany, Spain, Taiwan, United Kingdom
-
AlexionCompletedParoxysmal Nocturnal Hemoglobinuria (PNH)United States, Korea, Republic of, Canada, France, Germany, Spain, United Kingdom, Japan, Australia, Italy, Netherlands
-
Alexion Pharmaceuticals, Inc.RecruitingChronic Kidney Disease | CKD | Cardiopulmonary Bypass | Cardiac DiseaseUnited States, China, Germany, Italy, Korea, Republic of, Spain, Japan, Brazil, India, Taiwan, Australia, Israel, Hong Kong, United Kingdom, Poland, Argentina, Canada, Turkey, Netherlands
-
Alexion Pharmaceuticals, Inc.RecruitingParoxysmal Nocturnal HemoglobinuriaItaly
-
Alexion Pharmaceuticals, Inc.CompletedAtypical Hemolytic Uremic Syndrome (aHUS)Italy, United States, Korea, Republic of, Spain, Germany, Belgium, United Kingdom